



(PCT Article 18 and Rules 43 and 44)

pplicant's or agent's file reference	FOR FURTHER see Notification of (Form PCT/ISA/2)	f Transmittal of Internationa 20) as well as, where applic	able, item o batem
029441W0	International filing date (day/month/year)	(Earliest) Priority Date (d	ay/month/year)
ternational application No.		22/01/2	2002
CT/GB 03/00211	21/01/2003	2210112	
pplicant			
UROPEAN MOLECULAR BIOLO	GY LABORATORY		
This International Search Report has be according to Article 18. A copy is being	een prepared by this International Searching Au transmitted to the International Bureau.	thority and is transmitted to	the applicant
This International Search Report consider X It is also accompanied	sts of a total of <u>8</u> sheets. by a copy of each prior art document cited in th	s report.	
Induing in Which II Was lifed.	the international search was carried out on the bunders otherwise indicated under this item.		
the international search	h was carried out on the basis of a translation o	f the international application	n furnished to this
b. With regard to any nucleotide	e and/or amino acid sequence disclosed in the of the sequence listing:	international application, th	e international search
contained in the interr	national application in written form.		
filed together with the	international application in computer readable t	orm.	
T furnished subsequent	ty to this Authority in written form.		
	was this Authority in computer readble form.		colocura in the
the statement that the	subsequently furnished written sequence listin	g does not go beyond the di	Sciosure in the
the statement that the furnished	on as filed has been furnished. e information recorded in computer readable for	m is identical to the written s	equence usung has seen
	e found unsearchable (See Box I).		
3. X Unity of invention i	s lacking (see Box II).		
4. With regard to the title ,			
the text is approved	as submitted by the applicant.		
the text has been es	stablished by this Authority to read as follows:		
		•	
With regard to the abstract,			
the text is approved	d as submitted by the applicant. stablished, according to Rule 38.2(b), by this Ai om the date of mailing of this international searc	athority as it appears in Box th report, submit comments	III. The applicant may, to this Authority.
	be published with the abstract is Figure No.	ĪXĪ	None of the figures.
as suggested by the			Hono or the ng
because the applic	ant failed to suggest a figure.		
	e better characterizes the invention.		

Mication No Internatio 3/00211 PCT/GB-

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12N9/12 C12N15/62 A61K38/45

C12N15/11

C07K16/18 C12Q1/68

G01N33/50 G01N33/00 C12N5/10

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

 $\label{lem:mumdocumentation} \begin{tabular}{l} Minimum documentation searched (classification system followed by classification symbols) \\ IPC 7 C12N \end{tabular}$

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, EPO-Internal, WPI Data, PAJ, EMBASE

C. DOCUME	ENTS CONSIDERED TO BE RELEVANT	mlowant nassages	Relevant to claim No.
Category °	Citation of document, with indication, where appropriate, of the	e televant bassages	
Ρ,Χ	PLUK HELMA ET AL: "Autoinhibit c-Abl." CELL, vol. 108, no. 2, 24 January 2002 (2002-01-24), 247-259, XP001147512 January 24, 2002		1-27, 31-54
	ISSN: 0092-8674 The whole document. The document	nt was made	
	available to the public online EST on January 24 2002.	at 12 noon	
	EST Off Salidary 24 2002.		
		-/ - -	
		-	
			. Kata din conov
X F	urther documents are listed in the continuation of box C.	χ Patent family members	are listed in annex.
'A' docu	categories of cited documents: ment defining the general state of the art which is not sidered to be of particular relevance	"T" later document published aft or priority date and not in c cited to understand the prin invention "X" document of particular relev	nciple or theory underlying the
'E' earli	ier document but published on or after the international and date	"X" document of particular relev cannot be considered nove	or cannot be considered to then the document is taken alone
'L' docu	Iment which may throw doubts on priority claim(s) or lich is cited to establish the publication date of another ation or other special reason (as specified)	"Y" document of particular relev cannot be considered to in	vance; the claimed invention volve an inventive step when the
O' doc	nument referring to an oral disclosure, use, exhibition or ner means	ments, such combination t in the art.	being obvious to a person signor
IPI doc	turnent published prior to the international filing date but er than the priority date claimed	"&" document member of the s	
	the actual completion of the international search	Date of mailing of the inter	national search report
	5 June 2003	24/06/2003	
Name a	and mailing address, of the ISA European Patent Office, P.B. 5818 Patentlaan 2	Authorized officer	

Fax: (+31-70) 340-3016

2

European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,

Valcarcel, R

Internation Vication No PCT/GB 3/00211

		PC1/GB 43/00211
C.(Continuat	ion) DOCUMENTS CONSIDERED TO BE RELEVANT	Relevant to claim No.
Category °	Citation of document, with indication, where appropriate, of the relevant passages	
X	VAN ETTEN RICHARD A: "Cycling, stressed-out and nervous: Cellular	1-26, 31-41
	functions of c-Abl." TRENDS IN CELL BIOLOGY, vol. 9, no. 5, May 1999 (1999-05), pages	
A	179-186, XP002243530 ISSN: 0962-8924 the whole document	1-27, 31-54
x	WO 01 94408 A (EUROP MOLECULAR BIOLOGY LAB; SUPERTI FURGA GIULIO (DE); BARILA DAN)	1-26, 31-41
Α	13 December 2001 (2001-12-13) the whole document	27,42-54
X	WEN S-T ET AL: "The PAG gene product, a stress-induced protein with antioxidant properties, is an Abl SH3-binding protein properties, is an inhibitor of c-Abl	1-26, 31-41
	and a physiological inhibitor of c-Abl tyrosine kinase activity" GENES AND DEVELOPMENT, COLD SPRING HARBOR, NY, US,	
	voi. 11, no. 19, 1 October 1997 (1997-10-01), pages 2456-2467, XP002182087 ISSN: 0890-9369	07.42.54
Α	the whole document	27,42-54
X	TOPALY J ET AL: "SYNTERGISTIC ACTIVITY OF THE NEW ABL-SPECIFIC TYROSINE KINASE INHIBITOR ST1571 AND CHEMOTHERAPEUTIC DRUGS ON BCR-ABL-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA CELLS" LEUKEMIA, MACMILLAN PRESS LTD, US, vol. 15, May 2001 (2001-05), pages 342-347, XP001039741	1-26, 31-41
. A	ISSN: 0887-6924 the whole document	27,42-54
X	BARILA D ET AL: "AN INTRAMOLECULAR SH3-DOMAIN INTERACTION REGULATES C-ABL ACTIVITY"	1-26, 31-41
	NATURE GENETICS, NEW YORK, NY, US, vol. 18, March 1998 (1998-03), pages 280-282, XP001021006 ISSN: 1061-4036	27,42-54
A	the whole document	27,12
	_/	

Internation No PCT/GB 03/00211

	tion) DOCUMENTS CONSIDERED TO BE RELEVANT	
	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
ategory °		1-26,
	WALKENHORST JUERGEN ET AL: "Analysis of human c-Abl tyrosine kinase activity and regulation in S. pombe." ONCOGENE, vol. 12, no. 7, 1996, pages 1513-1520,	31-41
\	XP009011935 ISSN: 0950-9232 the whole document	27,42-54
A	DOREY KAREL ET AL: "Phosphorylation and structure-based functional studies reveal a positive and a negative role for the activation loop of the c-Abl tyrosine kinase." ONCOGENE, vol. 20, no. 56, 2001, pages 8075-8084, XP009011896 6 December, 2001 ISSN: 0950-9232	1-27, 31-54
Ā	the whole document WU J J ET AL: "Comparison of the intrinsic kinase activity and substrate specificity of c-Abl and Bcr-Abl" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS,	1-27, 31-54
	OXFORD, GB, vol. 8, no. 17, 8 September 1998 (1998-09-08), pages 2279-2284, XP004138218 ISSN: 0960-894X the whole document	
А	DOREY K ET AL: "REGULATION OF HUMAN C-ABL TYROSINE KINASE ACTIVITY IN XENOPUS OOCYTES AND ACCELERATION OF PROGESTERONE-INDUCED G2/M TRANSITION BY ONCOGENIC FORMS" BIOLOGICAL CHEMISTRY, XX, XX, vol. 380, no. 2, February 1999 (1999-02), pages 223-230, XP001022104 ISSN: 1431-6730 the whole document	1-27, 31-54
E	WO 03 031608 A (BRANFORD SUSAN ;HUGHES TIMOTHY (AU); RUDZKI ZBIGNIEW (AU); MEDVET) 17 April 2003 (2003-04-17) the whole document	1-26, 31-41

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-41,43,45-47,49-51,53,54 (all entirely); 42,44,48, 52 (all partially)

Tyrosine kinase inhbitor proteins, vectors comprising DNA endoding such inhibitors, methods involving said products, methods for activating c-Abl, for producing c-Abl, or for screening for a compound that restores autoinhibition of c-Abl in vivo.

c-Abl protein as defined in claims 42 and 43, wherein a protease cleave site is introduced by genetic engineering, nucleic acid as defined in claim 48, and a transgenic animal comprising a nucleic acid molecule according to claim 48.

2. Claims: 42,44,48,52 (all partially)

c-Abl protein as defined in claim 42, wherein a protease cleave site is not introduced by genetic engineering, nucleic acid as defined in claim 48, and a transgenic animal comprising a nucleic acid molecule according to claim 48.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Although claims 36-38 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Although claim 40 is directed to a diagnostic method comprising a method practised on the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.

Continuation of Box I.2

Claims Nos.: 28-31,33-38

Claims 28 and 30 relate to a product defined by being identified or identifiable by the methods of claims 27 and 29 respectively. Claim 29 refers to a method defined in terms of the activator of claim 28.

The claims cover all products having this characteristic or property, whereas the application provides no support within the meaning of Article 6 PCT nor disclosure within the meaning of Article 5 PCT for any of such products. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the product by reference to a product of manufacture. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Thus, the subject-matter of claims 28, 29, and 30 has not been searched.

Claims 31 and 33-38 make reference to the products of caims 28 and 30. Thus, the subject-matter of these claims referring to claims 28 and 30 has also not been searched.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.



Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)	
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:	
1. X Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely: see FURTHER INFORMATION sheet PCT/ISA/210	
2. X Claims Nos.: 28-31,33-38 because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically: See FURTHER INFORMATION sheet PCT/ISA/210	
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).	
Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)	
Box II Observations where unity of inventions to taking (This International Searching Authority found multiple inventions in this international application, as follows:	
see additional sheet	
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.	
2. X As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.	
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:	
No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:	
Remark on Protest The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.	

Informa

patent family members

Internation Discretion No PCT/GB 3/00211

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 0194408	A	13-12-2001	AU EP WO	7441601 A 1290022 A1 0194408 A1	17-12-2001 12-03-2003 13-12-2001
WO 03031608	Α	17-04-2003	WO	03031608 A2	17-04-2003